Rusfertide Nearly Eliminates Need for Phlebotomies to Treat Polycythemia Vera - Cancer Currents Blog

The latest from the NCI Cancer Currents blog

Having trouble viewing this email? View it as a Web page.

Rusfertide Nearly Eliminates Need for Phlebotomies to Treat Polycythemia Vera 03/28/2024 Adding rusfertide to treatment for polycythemia vera cut phlebotomy rates from nine to less than one per year in a recent clinical trial. The finding may improve the quality of life for those who manage the blood cancer with frequent blood draws. Read the Story You are subscribed to the latest posts from Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Update your subscriptions.

Stay Connected with the National Cancer Institute
Chat with us: LiveHelp  Call us: 1-800-4-CANCER (1-800-422-6237) SUBSCRIBER SERVICES: Manage Subscriptions  |  Help

 

This email was sent to edwardlorilla1986.paxforex@blogger.com using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892